Neurology® Podcast Aducanumab and the Business of Alzheimer Disease; Implicit Light Sensitivity in Migraine
Oct 25, 2021
Chapters
Transcript
Episode notes
1 2 3 4 5 6 7 8
Introduction
00:00 • 2min
The FDA Shouldn't Approve Aticanama Ut
02:21 • 2min
What I Will Teach My Patients About Can Mab
03:53 • 2min
Is There a Business Model for All Timers Disease?
05:47 • 2min
A Drug That Won't Even Be Approved - Is That a Good Thing?
07:31 • 3min
Is This a Drug That Should Be Dosed and to a Patient After Receiving a Prescription?
10:17 • 2min
Retno Alian Cell Signalling After the Retina
12:42 • 5min
Are There Shared Mechanisms That Lead to Photophobia?
17:59 • 3min